Literature DB >> 8695358

Soluble factors produced by PC-3 prostate cells decrease collagen content and mineralisation rate in fetal rat osteoblasts in culture.

J F Santibáñez1, S Silva, J Martínez.   

Abstract

Approximately 70% of patients with prostate cancer develop bone metastases in the advanced state of the disease. In the present study, we sought to test the hypothesis that prostatic cancer cells produce factors that inhibit the mineralisation process in vitro, decreasing the content of type I collagen in rat fetal calvaria osteoblasts. We investigated the capacity of conditioned media (CM) from the human prostatic tumour cell line PC-3 to inhibit the expression of the differentiation programme on osteoblasts in culture, with a primary focus on type I collagen synthesis and degradation. Our results show that PC-3 CM inhibits collagen synthesis and stimulates the production of interstitial collagenase from osteoblasts. A consequential decrease in the content of immunoreactive type I collagen was observed. We have previously demonstrated that PC-3 CM blocks osteoblast differentiation in culture. We propose that under the effect of factors present in PC-3 CM, osteoblastic cells retain the undifferentiated phenotype.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695358      PMCID: PMC2074652          DOI: 10.1038/bjc.1996.375

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  National Cancer Institute roundtable on prostate cancer: future research directions.

Authors:  A Chiarodo
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

Review 2.  The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation.

Authors:  P Angel; M Karin
Journal:  Biochim Biophys Acta       Date:  1991-12-10

3.  Some properties of the products of reaction of tadpole collagenase with collagen.

Authors:  T Sakai; J Gross
Journal:  Biochemistry       Date:  1967-02       Impact factor: 3.162

Review 4.  Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype.

Authors:  G S Stein; J B Lian
Journal:  Endocr Rev       Date:  1993-08       Impact factor: 19.871

5.  The influence of type I collagen on the development and maintenance of the osteoblast phenotype in primary and passaged rat calvarial osteoblasts: modification of expression of genes supporting cell growth, adhesion, and extracellular matrix mineralization.

Authors:  M P Lynch; J L Stein; G S Stein; J B Lian
Journal:  Exp Cell Res       Date:  1995-01       Impact factor: 3.905

6.  Expression of metalloproteinases and tissue inhibitors of metalloproteinases in human osteoblast-like cells: differentiation is associated with repression of metalloproteinase biosynthesis.

Authors:  L Rifas; A Fausto; M J Scott; L V Avioli; H G Welgus
Journal:  Endocrinology       Date:  1994-01       Impact factor: 4.736

7.  Calcification of differentiating skeletal mesenchyme in vitro.

Authors:  I Binderman; R M Greene; J P Pennypacker
Journal:  Science       Date:  1979-10-12       Impact factor: 47.728

8.  Regulation of interstitial collagenase expression and collagen degradation by retinoic acid in bone cells.

Authors:  S Varghese; S Rydziel; J J Jeffrey; E Canalis
Journal:  Endocrinology       Date:  1994-06       Impact factor: 4.736

9.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3).

Authors:  M E Kaighn; K S Narayan; Y Ohnuki; J F Lechner; L W Jones
Journal:  Invest Urol       Date:  1979-07

10.  Why does bone matrix contain non-collagenous proteins? The possible roles of osteocalcin, osteonectin, osteopontin and bone sialoprotein in bone mineralisation and resorption.

Authors:  H I Roach
Journal:  Cell Biol Int       Date:  1994-06       Impact factor: 3.612

View more
  1 in total

1.  Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption.

Authors:  J W Chiao; B S Moonga; Y M Yang; R Kancherla; A Mittelman; J R Wu-Wong; T Ahmed
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.